Rahul P Sharma,Dion Stub
Rahul P Sharma
Cardiac arrest is a major cause of morbidity and mortality and accounts for nearly 500,000 deaths annually in the United States. In patients suffering out-of-hospital cardiac arrest, survival is less than 15%, with considerable regional var...
Controversies and Challenges in the Management of ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock [0.03%]
STEMI并心源性休克诊疗的争议与挑战
Byung-Soo Ko,Stavros G Drakos,Frederick G P Welt et al.
Byung-Soo Ko et al.
The prognosis in ST-elevation myocardial infarction has improved with coronary care units, revascularization, and anticoagulant strategies; however, cardiogenic shock (CS) remains a highly fatal condition. Controversies remain about optimal...
Amerjeet S Banning,Anthony H Gershlick
Amerjeet S Banning
Cardiogenic shock represents a state of low cardiac output and systemic hypoperfusion resulting in insufficient end-organ perfusion and consequent multiorgan failure. The main cause of this complication in the context of acute ST-elevation ...
Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction [0.03%]
关于ST段抬高型心肌梗死女性患者治疗的争议
Vivian G Ng,Alexandra J Lansky
Vivian G Ng
Coronary artery disease is the leading cause of death in women. Women with ST-segment elevation myocardial infarctions continue to have worse outcomes compared with men despite advancements in therapies. Furthermore, these differences are p...
Controversies in the Management of ST-Segment Elevation Myocardial Infarction: Transradial Versus Transfemoral Approach [0.03%]
ST段抬高型心肌梗死经桡动脉与经股动脉入路的争议
Taylor C Bazemore,Sunil V Rao
Taylor C Bazemore
This article discusses the controversies surrounding the use of transradial versus transfemoral approaches in the management of patients with ST-segment elevation myocardial infarction, beginning with a review of the benefits of transradial...
Controversies in the Management of ST Elevation Myocardial Infarction: Thrombin Inhibition [0.03%]
ST段抬高型心肌梗死的治疗争议：抗凝疗法
Neeraj Shah,David Cox
Neeraj Shah
Anticoagulation is essential in patients with ST elevation myocardial infarction (STEMI) to prevent further thrombosis and to maintain patency of the infarct-related artery after reperfusion. The various anticoagulant medications available ...
Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction [0.03%]
ST段抬高心肌梗死的抗血小板治疗策略选择
Rafael Harari,Usman Baber
Rafael Harari
Cardiovascular disease is the leading cause of death worldwide. Case-fatality rates for myocardial infarction (MI) in the United States have decreased over the past decades, in large part due to advances in the treatment of acute MI and sec...
In-Hospital ST Elevation Myocardial Infarction: Clinical Characteristics, Management Challenges, and Outcome [0.03%]
急性ST段抬高型心肌梗死的临床特点、治疗挑战及预后分析
Xuming Dai,Ross F Garberich,Brian E Jaski et al.
Xuming Dai et al.
Timely reperfusion therapy reduces complications and improves survival in ST elevation myocardial infarction (STEMI). An effective chain of survival has been established for STEMIs occur in the community (outpatient STEMI). Recent studies h...
David C Lange,Ivan C Rokos,J Lee Garvey et al.
David C Lange et al.
First-medical-contact-to-device (FMC2D) times have improved over the past decade, as have clinical outcomes for patients presenting with ST-elevation myocardial infarction (STEMI). However, with improvements in FMC2D times, false activation...
Reperfusion Options for ST Elevation Myocardial Infarction Patients with Expected Delays to Percutaneous Coronary Intervention [0.03%]
预期经皮冠状动脉介入治疗延迟的ST段抬高型心肌梗死患者的再灌注选择
David M Larson,Peter McKavanagh,Timothy D Henry et al.
David M Larson et al.
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST elevation myocardial infarction (STEMI). However, only one-third of hospitals in the US have PCI availability 24/7. For non-PCI hospitals, transfe...